Exhibit 99.1 SelectQuote, Inc. Reports First Quarter of Fiscal Year 2026 Results First Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights First Quarter Fiscal Year 2026 – Segment Highlights Senior Healthcare Services Life OVERLAND PARK, Kan., November 6, 2025--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the first quarter of fiscal year 2026 of $328.8 million compared to consolidated revenue for the first quarter of fiscal year 2025 of $292.3 million. Consoli ...

Exhibit 99.1 Cronos Group Reports 2025 Third Quarter Results Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA Net revenue in Q3 2025 increased by 9% quarter-over-quarter and 6% year-over-year Generated record-high net revenue in Israel, where PEACE NATURALS remains the number one cannabis brand ® 1 Industry-leading balance sheet with $824 million in total cash and cash equivalents and short-term investments TORONTO, November 6, 2025 - Cronos Group Inc. (NASDAQ: CRON) (TSX ...

Exhibit 99.1 UNDER ARMOUR REPORTS SECOND QUARTER FISCAL 2026 RESULTS; PROVIDES FISCAL 2026 OUTLOOK BALTIMORE, Nov. 6, 2025 – Under Armour, Inc. (NYSE: UAA, UA) released its unaudited financial results for the second quarter of fiscal 2026, which ended on September 30, 2025. The company reports its financial performance in accordance with Generally Accepted Accounting Principles in the United States ("GAAP"). This press release includes references to "currency neutral" and "adjusted" amounts, which are non-G ...

Exhibit 99.1 Second Quarter Fiscal 2026 Review • Revenue decreased 5 percent to $1.3 billion (down 6 percent currency neutral). – North American revenue declined 8 percent to $792 million, while international revenue grew 2 percent to $551 million (down 1 percent currency neutral). Within the international business, revenue in EMEA increased 12 percent (up 7 percent currency neutral), decreased 14 percent in Asia-Pacific (down 14 percent currency neutral), and grew 15 percent in Latin America (up 14 percent ...

FOR IMMEDIATE RELEASE Alpha Announces Third Quarter 2025 Financial Results • Reports third quarter net loss of $5.5 million | | (millions, except per share) | | | | --- | --- | --- | --- | | | Three months ended | | | | | Sep. 30, 2025 | June 30, 2025 | Sep. 30, 2024 | | Net (loss) income | ($5.5) | ($5.0) | $3.8 | | Net (loss) income per diluted share | ($0.42) | ($0.38) | $0.29 | | (1) Adjusted EBITDA | $41.7 | $46.1 | $49.0 | | Operating cash flow | $50.6 | $53.2 | $189.5 | | Capital expenditures | ($25. ...

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update – Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 2040 – ® ® – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dysl ...

MACOM Reports Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results LOWELL, MA, November 6, 2025 – MACOM Technology Solutions Holdings, Inc. ("MACOM") (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended October 3, 2025. Fiscal Year 2025 GAAP Results Fiscal Year 2025 Adjusted Non-GAAP Results • Revenue was $261.2 million, an increase of 30.1%, compared to $200.7 million in the previous year fiscal fourt ...

Revenue Performance - KIMMTRAK® net revenues reached $103.7 million in Q3 2025, a 29% increase year-over-year[1] - The company reported a total of $295.5 million in KIMMTRAK sales for the nine months ended September 30, 2025, representing a 31% increase compared to the same period in 2024[8] - The U.S. experienced an 18% year-over-year quarterly sales growth, with the mean duration of treatment increasing to 14 months[8] - European and international sales grew by 58% year-over-year, driven by increased demand and market launches[8] - Total revenue for the quarter ended September 30, 2025, was $103.693 million, a 29.2% increase from $80.248 million in the same quarter of 2024[47] - Revenue from the sale of therapies for the year to date was $295.538 million, compared to $225.937 million for the same period in 2024, reflecting a 30.7% increase[47] Expenses and Financial Loss - Research and development expenses for Q3 2025 were $70.6 million, up from $52.8 million in Q3 2024, due to advancements in autoimmune programs and Phase 3 trials[21] - Selling, general and administrative expenses increased to $39.8 million in Q3 2025 from $35.5 million in Q3 2024, primarily for business support functions[22] - The company reported a net loss of $0.2 million for Q3 2025, compared to a net profit of $8.7 million in Q3 2024[23] - The net loss for the quarter was $177,000, compared to a net income of $8.736 million in the same quarter of 2024[47] - The basic net loss per share for the quarter was $(0.00), compared to a basic net income per share of $0.17 in the prior year[47] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $892 million as of September 30, 2025, up from $820.4 million at the end of 2024[24] - Total current assets amounted to $1,022,848,929, an increase from $1,009,506,000[48] - Cash and cash equivalents reached $498,413,000, up from $455,731,000[48] - Total assets increased to $1,102,500,000 from $1,009,506,000[48] - Total equity for shareholders was $396,564,360, an increase from $716,000[48] Liabilities - Total liabilities stood at $705,936,000, compared to $648,790,000 previously[48] - Current liabilities totaled $170,353,221, an increase from $181,000[48] - Accounts payable decreased to $22,956,000 from $25,100,000[48] - Deferred revenue, current, was reported at $582,000, compared to $547,000[48] Clinical Trials and Product Development - The company is advancing three Phase 3 melanoma trials and multiple mid-stage programs to enhance patient outcomes and shareholder value[2] - The Independent Data Monitoring Committee recommended a 160 mcg dose for the brenetafusp in the Phase 3 PRISM-MEL-301 trial[8] - KIMMTRAK has been approved for treatment in multiple regions, including the United States, European Union, Canada, Australia, and the United Kingdom[36] - The company is focused on expanding KIMMTRAK's indications and global market presence, targeting advanced cutaneous melanoma and adjuvant uveal melanoma[45] Patient Outcomes and Side Effects - 89% of patients receiving KIMMTRAK experienced Cytokine Release Syndrome (CRS), with 0.8% classified as grade 3 or 4[37] - Skin reactions occurred in 91% of patients treated with KIMMTRAK, necessitating monitoring and potential treatment[38] - Elevations in liver enzymes were reported in 65% of patients treated with KIMMTRAK, requiring careful monitoring[39] Cash Flow Activities - Net cash provided by operating activities decreased to $21,943,000 from $40,012,000 year-over-year[50] - Net cash used in investing activities significantly decreased to $(15,460,000) compared to $(351,589,000) in the prior year[50] - Net cash provided by financing activities decreased to $8,087,000 from $395,392,000 year-over-year[50] - Cash and cash equivalents at the beginning of the period were $455,731,000, an increase from $442,626,000 in the previous year[50] - Cash and cash equivalents at the end of the period (September 30) were $498,413,000, down from $537,767,000 in the previous year[50] - Net foreign exchange difference on cash held increased to $28,112,000 from $11,326,000 year-over-year[50]

Financial Performance - Total revenues for Q3 2025 were $29.733 million, a 23.5% increase from $24.197 million in Q3 2024[18] - License and royalty revenue for Q3 2025 was $23.605 million, slightly down from $23.982 million in Q3 2024[18] - Net loss for Q3 2025 was $61.941 million, compared to a net loss of $59.597 million in Q3 2024, representing a 3.9% increase in loss[18] - The company reported a comprehensive loss of $61.843 million for Q3 2025, compared to a comprehensive loss of $57.913 million in Q3 2024[18] - The company generated a net cash used in operating activities of $71.7 million for the nine months ended September 30, 2025, an improvement from $141.5 million in the prior year[26] - The Company reported revenues of $29.7 million for the three months ended September 30, 2025, compared to $24.2 million for the same period in 2024, representing a 22.5% increase[139] Assets and Liabilities - Total assets increased to $525.203 million as of September 30, 2025, up from $465.989 million at the end of 2024, reflecting a 12.8% growth[17] - Total liabilities rose significantly to $363.751 million as of September 30, 2025, compared to $206.338 million at the end of 2024, marking a 76.2% increase[17] - The accumulated deficit as of September 30, 2025, was $1.058 billion, an increase from $932.149 million at the end of 2024[17] - Cash and cash equivalents increased to $58.802 million as of September 30, 2025, from $57.526 million at the end of 2024[17] - The company had cash, cash equivalents, and marketable securities totaling $302.0 million as of September 30, 2025, which is expected to fund operations for at least the next 12 months[30] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $168.688 million, up from $158.142 million in the same period of 2024[18] - Research and development expenses rose to $56.1 million in Q3 2025, up $1.7 million from $54.4 million in Q3 2024, despite a $3.7 million decrease in clinical trial costs[209] - The increase in research and development expenses was partially offset by a decrease of $4.6 million in costs associated with clinical trials and regulatory activities[215] Revenue Recognition and Agreements - Revenue is recognized in accordance with ASC 606, requiring the transfer of control of goods or services to customers[43] - The transaction price for license and collaboration agreements includes fixed and variable considerations, with milestone payments included if probable[52][54] - The Company received an up-front fee of $370.0 million from AbbVie under the collaboration agreement, with potential milestone payments of up to $1.38 billion[108] - The Company entered into a collaboration and license agreement with Nippon Shinyaku, receiving an up-front fee of $110.0 million and up to $700.0 million in milestone payments[116] - The Company recognized total revenues of $80.4 million under the Nippon Shinyaku Collaboration Agreement for the nine months ended September 30, 2025[123] Stock and Compensation - Stock-based compensation expense for the nine months ended September 30, 2025, was $26.2 million, slightly lower than the $28.9 million reported for the same period in 2024[26] - The total intrinsic value of restricted stock units vested during the nine months ended September 30, 2025, was $5.9 million[132] - The Company had $57.2 million of unrecognized stock-based compensation expense expected to be recognized over a weighted-average period of 2.3 years[128] Collaboration and Licensing - The NAV Technology Platform is being utilized by licensees in one commercial product, Zolgensma®, and in the development of several other licensed products[29] - The Company has selectively licensed its NAV Technology Platform to other biotechnology and pharmaceutical companies, indicating ongoing collaboration and market expansion efforts[29] - The Company retains all rights to any priority review vouchers that may be issued upon potential approvals of RGX-121 and RGX-111[116] Expenses - General and administrative expenses increased to $20.3 million in Q3 2025 from $19.4 million in Q3 2024, driven by higher professional services and consulting costs[210] - Interest expense surged to $13.2 million in Q3 2025, up from $0.8 million in Q3 2024, primarily due to increased interest under royalty monetization liabilities[212] Future Outlook - The company expects general and administrative expenses to increase as it prepares for the potential commercialization of product candidates, particularly RGX-202 and ABBV-RGX-314[186] - Future revenues from licensing agreements are uncertain and may fluctuate significantly due to the contingent nature of payments[175]

Financial Performance - The company has not generated any revenue from product sales since its inception in February 2022 and has incurred significant operating losses, with net losses of $26.9 million and $17.5 million for the three months ended September 30, 2025 and 2024, respectively[146][150]. - The net loss for the three months ended September 30, 2025, was $26.925 million, compared to a net loss of $17.537 million for the same period in 2024, indicating a $9.388 million increase in losses[177]. - Net loss for the nine months ended September 30, 2025, was $77.7 million, compared to a net loss of $58.3 million in 2024, an increase of $19.4 million[183]. - Interest income decreased to $3.061 million for the three months ended September 30, 2025, down from $4.103 million in 2024, a decline of $1.042 million[177]. - Other income decreased to $3.1 million for the three months ended September 30, 2025, down from $4.1 million in 2024, primarily due to reduced interest income from lower cash and investment balances[179]. Cash and Financing - As of September 30, 2025, the company had raised aggregate gross proceeds of $711.9 million from financings and had cash, cash equivalents, and short-term investments of $513.0 million, excluding restricted cash[149]. - The company completed an underwritten public offering in September 2025, raising approximately $269.4 million in net proceeds after deducting offering costs[149]. - Net cash provided by financing activities was $270.5 million for the nine months ended September 30, 2025, primarily from the September 2025 Offering[195]. - The company believes its existing cash and cash equivalents will fund operations into the second half of 2029[153]. - The company expects its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months[197]. Research and Development - The company plans to initiate an open-label long-term safety trial for RAP-219 by the end of 2025, with preliminary results expected in the second half of 2026[142]. - The Phase 2a trial of RAP-219 in drug-resistant focal onset seizures met its primary and secondary endpoints, demonstrating a statistically significant reduction in clinical seizures compared to baseline[142]. - The company is developing a long-acting injectable formulation of RAP-219 to improve patient adherence and expand clinical utility across indications[144]. - The Investigational New Drug application for a Phase 2 trial of RAP-219 for diabetic peripheral neuropathic pain is on clinical hold pending additional information requested by the FDA[143]. - Research and development expenses increased to $22.3 million for the three months ended September 30, 2025, compared to $15.5 million for the same period in 2024, representing a $6.7 million increase[177]. - The increase in research and development expenses included a $3.1 million rise in RAP-219 program costs, driven by clinical trial costs for the Phase 2a trial and open-label long-term safety trial[178]. - The company expects research and development expenses to increase substantially as it advances RAP-219 through clinical development and pursues regulatory approval[164]. - Research and development expenses rose to $64.5 million for the nine months ended September 30, 2025, compared to $43.7 million in 2024, marking an increase of $20.8 million[184]. - The RAP-219 program costs increased by $12.0 million, driven mainly by clinical trial costs for various Phase 2 trials[184]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $29.986 million, up from $21.640 million in 2024, reflecting an increase of $8.346 million[177]. - Total operating expenses for the nine months ended September 30, 2025, were $86.6 million, up from $59.5 million in 2024, reflecting a $27.1 million increase[183]. - General and administrative expenses increased to $7.7 million for the three months ended September 30, 2025, up from $6.1 million in the same period of 2024, representing a $1.6 million increase[179]. - The company anticipates that general and administrative expenses will increase due to hiring additional personnel and compliance-related costs associated with being a public company[170]. Collaborations and Agreements - The company has a collaboration agreement with Janssen Pharmaceutical NV, which includes potential milestone payments of up to $76.0 million for development and $40.0 million for sales of TARPg8 products[157]. - The company made a non-refundable payment of $1.0 million to Janssen and an additional option fee of $4.0 million, with potential milestone payments totaling up to $141.0 million for product development and sales[203]. - The company has entered into a master services agreement with NeuroPace Inc., which includes a payment of up to $5.3 million over approximately four years for services related to the RAP-219 clinical trials[161]. - Cumulative expenses incurred under the NeuroPace agreement amount to $3.4 million through September 30, 2025, with a total payment commitment of up to $5.3 million over four years[204]. Future Outlook and Risks - The company expects its expenses and operating losses to increase substantially as it continues clinical trials and research activities[151]. - The company anticipates substantial increases in expenses related to ongoing preclinical studies and clinical trials, with funding needs dependent on various factors[199]. - The company may need to raise additional capital through equity offerings or debt financings, which could dilute ownership interests and impose restrictions on operations[199]. - Future minimum operating lease payments under non-cancelable leases amount to $14.0 million, with a weighted average remaining lease term of 4.8 years[200][202]. - The company has recorded a full valuation allowance against its net deferred tax assets, indicating uncertainty about the realization of these assets[175]. - As of December 31, 2024, the company had federal net operating loss carryforwards of approximately $13.7 million and state net operating loss carryforwards of approximately $12.0 million[174]. Accounting and Compliance - The company has not experienced material changes to its critical accounting policies and estimates during the nine months ended September 30, 2025[207]. - The company has elected not to "opt out" of the extended transition period for new accounting standards, which may affect comparability with other public companies[208][209]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[211].